Last reviewed · How we verify
BGB-DXP593
BGB-DXP593 is a small molecule inhibitor targeting the CD73 enzyme.
BGB-DXP593 is a small molecule inhibitor targeting the CD73 enzyme. Used for Solid tumors.
At a glance
| Generic name | BGB-DXP593 |
|---|---|
| Sponsor | BeiGene |
| Drug class | CD73 inhibitor |
| Target | CD73 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CD73 is a key enzyme involved in the production of adenosine, which plays a role in tumor immune evasion. By inhibiting CD73, BGB-DXP593 aims to reduce adenosine levels and enhance anti-tumor immune responses.
Approved indications
- Solid tumors
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants (PHASE1)
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19) (PHASE2)
- Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |